Maya Frutiger
Head of Corporate Communications
maya.frutiger@us.sumitomo-pharma.com
News Releases
Stay up to date with SMPA
The latest company news, press releases, and resources about Sumitomo Pharma America, our employees, our partners, and our latest innovations.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Apr 12, 2021•SERENE is a Phase 3 single-arm, open-label study evaluating the contraceptive efficacy of investigational relugolix combination tablet in sexually active, healthy women ages 18-35 years
BASEL, Switzerland and NEW YORK, April 12, 2021 (GLOBE NEWSWIRE) Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3...
-
Apr 2, 2021Nationwide availability gives healthcare providers and patients a new treatment option
IRVINE, Calif. & BASEL, Switzerland–(BUSINESS WIRE)– Urovant Sciences, a biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today...
-
Mar 29, 2021•If approved, relugolix would be the first and only oral androgen deprivation therapy for advanced prostate cancer in Europe
BASEL, Switzerland, March 29, 2021 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the European Medicines...
-
Feb 17, 2021•LIBERTY 1 and LIBERTY 2 achieved 73.4% and 71.2% response rates in menstrual blood loss, with an average reduction of 84.3% from baseline
NEW YORK, LONDON, February 17, 2021 (GLOBE NEWSWIRE) — Sumitovant Biopharma Ltd., a majority shareholder of Myovant Sciences (NYSE: MYOV), announced today that the New England Journal of...
-
Feb 16, 2021•Six women reflect on their period experiences and journeys to self-advocacy in new video series
RED BANK, N.J. and BASEL, Switzerland, Feb. 16, 2021 (GLOBE NEWSWIRE) — HealthyWomen, the nation’s leading independent, nonprofit health information source for women, and Myovant Sciences...
-
Jan 5, 2021
BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that ORGOVYX™...
-
Dec 28, 2020•Myovant and Pfizer to jointly develop and commercialize ORGOVYXTM (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and Canada
NEW YORK and LONDON, Dec. 28, 2020 (GLOBE NEWSWIRE) — Sumitovant Biopharma Ltd., the majority shareholder of Myovant Sciences (NYSE: MYOV), announced today that Myovant Sciences, a healthcare...
-
Dec 23, 2020•GEMTESA is the first new oral branded OAB medication approved by the U.S. FDA since 2012 and the first product approval for Urovant Sciences
IRVINE, Calif. & BASEL, Switzerland–(BUSINESS WIRE)–Dec. 23, 2020– Urovant Sciences (Nasdaq: UROV) announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug...
-
Dec 17, 2020•ORGOVYX demonstrated a 96.7% response rate in testosterone suppression to castrate levels (< 50 ng/dL) through 48 weeks in the Phase 3 HERO study
BASEL, Switzerland, Dec. 18, 2020 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that the U.S. Food and...
-
Dec 10, 2020
MARLBOROUGH, Mass., December 10, 2020 1:15 pm (BUSINESS WIRE) — Sunovion Pharmaceuticals Inc. (Sunovion) today announced that new data and analyses of late-stage compounds SEP-363856 and...
-
Jun 29, 2020
MARLBOROUGH, Mass., June 29, 2021 at 9:00 AM EDT (BUSINESS WIRE) — Sunovion Pharmaceuticals Inc. (Sunovion) today announced topline results from study SEP380-201, a global, multicenter,...
-
May 29, 2020•Phase 3 data presented in oral presentation during the ASCO20 Virtual Scientific Program, with simultaneous publication in the New England Journal of Medicine
BASEL, Switzerland, May 29, 2020 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced additional results from...
-
Apr 15, 2020—Significantly greater improvement in the Positive and Negative Symptom Scale was demonstrated in schizophrenia patients treated with SEP-363856, a TAAR1 agonist, compared to placebo—
MARLBOROUGH, Mass., April 15, 2020 5:04 pm (BUSINESS WIRE) — Sunovion Pharmaceuticals Inc. (Sunovion) today announced that results of a four-week pivotal study (SEP361-201) evaluating the safety...
-
Mar 31, 2020•Gedeon Richter to commercialize relugolix combination tablet for uterine fibroids and endometriosis in Europe, Russia – CIS, Latin America, Australia, and New Zealand
BASEL, Switzerland and BUDAPEST, Hungary, March 31, 2020 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women’s health...